Skip to main content
. Author manuscript; available in PMC: 2014 Jun 24.
Published in final edited form as: Brain Res. 2010 Jun 1;1347:125–131. doi: 10.1016/j.brainres.2010.05.075

Fig. 1.

Fig. 1

Effects of 3K3A-APC and wt-APC therapies on motor neurological and complex sensorimotor outcomes determined by rotarod neuromotor (A) and beam balance (B) tests, respectively. 3K3A-APC or wt-APC were administered at 0.8 mg/kg I.P. 6 h after injury and subsequently at 12, 24 and 48 h after injury. Control mice were treated with saline (vehicle). Data are means±S.E.M., n=15 for APC-treated mice/groups, and n=10 for saline-treated mice; ap<0.05 for 3K3A-APC or wt-APC compared to saline; bp<0.05 for 3K3A-APC vs. wt-APC, Tukey post hoc test.